Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

Nanobody directed towards the human A1 domain of von Willebrand factor

EU orphan designation number: EU/3/09/629   
Active ingredient: Nanobody directed towards the human A1 domain of von Willebrand factor
Indication: Treatment of thrombotic thrombocytopenic purpura
Sponsor: Ablynx N.V.
Technologiepark 21, B-9052 Zwijnaarde, België

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
05/05/2009 Centralised Orphan - Designation EMEA/OD/109/08 (2009)3525 of 30/04/2009
17/08/2010 Other procedure EMA/409031/2010